Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Callisto Pharmaceuticals has expanded of its ongoing phase I/IIa clinical trial of L-Annamycin to treat adult patients with relapsed or refractory acute lymphocytic leukemia.
Subscribe to our email newsletter
The expanded trial will now utilize an additional clinical trial site, the Montefiore Medical Center, New York, a leading cancer research center in the US
“Montefiore Medical Center is a preeminent institution for the study of cancer, and we are very gratified that this site has joined the clinical trial of L-Annamycin, providing an additional pool of potential patients for the present study,” said Dr Donald Picker, Callisto’s executive vice president of R&D.
In previous animal studies, L-Annamycin has demonstrated that it can kill tumor cells that are resistant to other anthracycline anticancer drugs. In addition, earlier studies have shown that L-Annamycin may have other key advantages over other anthracycline drugs, including a decreased risk of treatment-related cardiomyopathy (inflammation of the heart muscle), a complication associated with this family of anticancer drugs.